UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

 

Evoke Pharma, Inc.

(Name of Issuer)

 

 

Common Stock, par value $0.0001

(Title of Class of Securities)

 

 

30049G302

(CUSIP Number)

 

 

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[ ]       Rule 13d-1(b)

 

[X]       Rule 13d-1(c)

 

[ ]       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

1.

Names of Reporting Persons. Laurence W. Lytton

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions) (a) ______ (b) ______

 

3. SEC Use Only

 

4.

Citizenship or Place of Organization USA

 

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power 74,757
	6. Shared Voting Power 0
	7. Sole Dispositive Power 74,757
	8. Shared Dispositive Power 0

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person 74,757

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

 

11.

Percent of Class Represented by Amount in Row (9) 9.99%

 

12.

Type of Reporting Person (See Instructions) IN

 

Item 1.

 

(a)

Name of Issuer Evoke Pharma, Inc.

 

(b)

Address of Issuer's Principal Executive Offices 420 Stevens Avenue, Suite 370, Solana Beach, CA 92075

 

Item 2.

 

(a)

The names of the persons filing this statement are: Laurence W. Lytton

(b)

The principal business office of the Filers is located at: 467 Central Park West New York, NY 10025

 

(c)

For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

 

(d)

This statement relates to shares of Common Stock, par value $0.0001 of the Issuer (the "Stock").

 

(e)

The CUSIP number of the Issuer is: 30049G302

Item 3.

If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)

[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)

[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)

[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

(e)

[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

 

(f)

[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

 

(g)

[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

 

(h)

[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i)

[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j)

[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

 

(k)

[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

 

Item 4.

Ownership.

 

See Items 5-9 and 11 of the cover page.

 

The shares of Common Stock beneficially owned by the reporting person consist of 61,274 shares of Common Stock, Class A Warrants to acquire 61,274 shares of Common Stock, Class B Warrants to acquire 61,274 shares of Common Stock and Class C Warrants to acquire 61,274 shares of Common Stock. The Class A Warrants, Class B Warrants and Class C Warrants are subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 734,836 shares of Common Stock outstanding as of August 8, 2024, as reported in the Form 10-Q filed by the Issuer on August 13, 2024.

 

Item 5.

Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.

Notice of Dissolution of Group

 

Not applicable.

 

Item 10.

Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: November 14, 2024

 

/s/ Laurence W. Lytton Laurence W. Lytton